The fifth and most recently FDA approved CAR-T cell therapy is idecabtagene vicleucel, trade name Abecma, with a CAR against B-cell maturation antigen (BCMA), for the treatment of adult patients with relapsed or refractory MM after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody [109]. Here, TNFRSF17 is linked to Miyoshi myopathy.